AUA 2011 - Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle invasive bladder cancer: A multidisciplinary approach - Session Highlights

WASHINGTON, DC USA ( - Delaying cystectomy >90 days from the diagnosis of muscle invasive bladder cancer (MIBC) adversely affects pathologic stage and survival outcomes in patients treated with primary surgery.

After neoadjuvant chemotherapy (NAC), the impact of the timing of cystectomy delivery on these outcomes is unknown. Median time to cystectomy from the first and last day of NAC was 16.6 weeks and 6.9 weeks respectively. In univariate analysis, pathologic stage, LVI and NAC regimen were associated with overall survival. In multivariate analysis, only pathologic stage remained significant. The timing of cystectomy delivery after NAC did not significantly alter overall survival in this cohort. Patient sample size was most robust within 10 weeks of NAC termination.

The authors conclude that performing a cystectomy within 10 weeks of completing NAC is acceptable.



Presented by Ajjai Alva, et al. at the American Urological Association (AUA) Annual Meeting - May 14 - 19, 2011 - Walter E. Washington Convention Center, Washington, DC USA

Reported for UroToday by David P. Wood Jr., MD, Professor, Department of Urology, University of Michigan Health System.


The opinions expressed in this article are those of the Contributing Editor and do not necessarily reflect the viewpoints of the American Urological Association.



View Full AUA 2011 Meeting Coverage